BR0311939A - composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico - Google Patents
composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánicoInfo
- Publication number
- BR0311939A BR0311939A BRPI0311939-4A BR0311939A BR0311939A BR 0311939 A BR0311939 A BR 0311939A BR 0311939 A BR0311939 A BR 0311939A BR 0311939 A BR0311939 A BR 0311939A
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- pharmaceutical composition
- inflammation
- organic tissue
- treating inflammation
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title abstract 4
- 108090000695 Cytokines Proteins 0.000 title abstract 4
- 206010061218 Inflammation Diseases 0.000 title abstract 4
- 230000004054 inflammatory process Effects 0.000 title abstract 4
- 241000124008 Mammalia Species 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000001681 protective effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 230000002669 organ and tissue protective effect Effects 0.000 abstract 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 238000011284 combination treatment Methods 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/188,905 US20030072737A1 (en) | 2000-12-29 | 2002-07-03 | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| PCT/US2003/021350 WO2004004656A2 (en) | 2002-07-03 | 2003-07-03 | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0311939A true BR0311939A (pt) | 2007-05-08 |
Family
ID=30114016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0311939-4A BR0311939A (pt) | 2002-07-03 | 2003-07-03 | composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20030072737A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1575528A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006515268A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20050049467A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1852731A (cg-RX-API-DMAC7.html) |
| AR (1) | AR040396A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003247934A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0311939A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2491406A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA010371B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL166067A0 (cg-RX-API-DMAC7.html) |
| IS (1) | IS7619A (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05000060A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20050550L (cg-RX-API-DMAC7.html) |
| PL (1) | PL377146A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004004656A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200500131B (cg-RX-API-DMAC7.html) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| US7345019B1 (en) * | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| US7767643B2 (en) * | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| MXPA05000063A (es) * | 2002-07-01 | 2005-04-08 | Kenneth S Warren Inst Inc | Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores. |
| WO2004022593A2 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| US20060216757A1 (en) * | 2003-04-25 | 2006-09-28 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| JP2007505159A (ja) * | 2003-05-19 | 2007-03-08 | ザ ケネス エス.ウォーレン インスティテュート,インコーポレーテッド | 延長された治療ウインドウを有する、応答性細胞、組織および器官の保護、回復および増強のための組織保護サイトカイン |
| CN1897959A (zh) * | 2003-09-29 | 2007-01-17 | 沃伦药品公司 | 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子 |
| US7101679B2 (en) | 2003-11-25 | 2006-09-05 | Mayo Foundation For Medical Education And Research | Marker for neuromyelitis optica |
| US20060135754A1 (en) * | 2004-07-07 | 2006-06-22 | H. Lundbeck A/S | Novel carbamylated EPO and method for its production |
| EP1781697B1 (en) * | 2004-07-07 | 2009-04-22 | H.Lundbeck A/S | Novel carbamylated epo and method for its production |
| AT500929B1 (de) | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | Pharmazeutische zubereitung die erythropoietin enthält |
| CN101247822B (zh) * | 2005-06-01 | 2012-10-17 | 新潟Tlo株式会社 | 含有epo衍生物的血液相关疾病的治疗剂 |
| EP1924276A4 (en) | 2005-08-05 | 2009-07-22 | Araim Pharmaceuticals Inc | Antiperspirant peptides and their uses |
| US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
| WO2007096782A2 (en) * | 2006-02-22 | 2007-08-30 | Valorisation Recherche Hscm, Limited Partnership | Compositions for disorders associated wtth metachromatic cell activation |
| GR1005808B (el) * | 2006-11-27 | 2008-02-06 | Bionature E.A. Limited | Επιταση της δρασεως της ερυθροποιητινης με αγωνιστες των μεμβρανικων στεροειδων υποδοχεων |
| WO2008065372A2 (en) | 2006-11-28 | 2008-06-05 | Nautilus Biotech, S.A. | Modified erythropoietin polypeptides and uses thereof for treatment |
| AR060424A1 (es) * | 2007-04-11 | 2008-06-18 | Consejo Nac Invest Cient Tec | Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento |
| US20110123481A1 (en) | 2007-08-16 | 2011-05-26 | Remedor Biomed Ltd. | Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications |
| JP5668476B2 (ja) | 2007-10-08 | 2015-02-12 | オーリニア・ファーマシューティカルズ・インコーポレイテッドAurinia Pharmaceuticals Inc. | カルシニューリン阻害剤またはmTOR阻害剤を含む眼科用組成物 |
| WO2009094172A2 (en) | 2008-01-22 | 2009-07-30 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| JP5829400B2 (ja) * | 2008-01-24 | 2015-12-09 | レメドー バイオメッド リミテッド | 骨再生のためのエリスロポイエチンおよびフィブロネクチン組成物 |
| WO2009102021A1 (ja) * | 2008-02-14 | 2009-08-20 | Kyoto University | 骨髄由来幹細胞、前駆細胞機能賦活による網膜疾患治療 |
| EP2310038A4 (en) * | 2008-05-15 | 2012-03-14 | Edison Pharmaceuticals Inc | TREATMENT OF HEARING AND BALANCE OF IMPROVENCE WITH COMPOUNDS WITH ERYTHROPOETIN EFFECT |
| US8278418B2 (en) | 2008-09-26 | 2012-10-02 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
| EP2440185B1 (en) * | 2009-06-09 | 2015-04-08 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
| KR101924162B1 (ko) * | 2010-03-15 | 2018-11-30 | 버지니아 커먼웰스 유니버시티 | 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손 |
| WO2012003960A1 (en) * | 2010-07-06 | 2012-01-12 | Augustinus Bader | Topical application of erythropoietin for the treatment of eye disorders and injuries |
| WO2012069474A2 (en) | 2010-11-24 | 2012-05-31 | H. Lundbeck A/S | A method for reducing potential virus burden in a sample by cyanate treatment |
| EP2736530B1 (en) * | 2011-07-27 | 2018-06-06 | Neumedicines, Inc | Use of il-12 to generate endogenous erythropoietin |
| HK1205964A1 (en) * | 2012-03-01 | 2015-12-31 | Medical Device Works Nv | Kit and devices for organ perfusion |
| JP2012193207A (ja) * | 2012-07-13 | 2012-10-11 | New York Univ | インターフェロンを用いる肺疾患の処置方法 |
| GB201214007D0 (en) * | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
| DK2956056T3 (da) | 2013-03-14 | 2019-09-16 | Univ Laval | Elektroretinografisystem (erg) til vurdering af psykiatriske lidelser |
| CN104232571B (zh) * | 2014-01-29 | 2018-01-12 | 中国人民解放军第二军医大学 | 一种组织工程化搏动组织的构建方法 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| JP2019523633A (ja) | 2016-04-29 | 2019-08-29 | アライム ファーマシューティカルズ,インコーポレーテッド | 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| WO2019149245A1 (zh) * | 2018-02-01 | 2019-08-08 | 江苏恒瑞医药股份有限公司 | 含人胰岛素类似物的酰化衍生物的药物组合物及其制备方法 |
| GB201815041D0 (en) | 2018-09-14 | 2018-10-31 | Scancell Ltd | Epitopes |
| BR112022019113A2 (pt) | 2020-03-26 | 2022-12-06 | Diamentis Inc | Sistemas e métodos para processar dados de sinal da retina e identificar condições |
| CN113648418B (zh) * | 2021-05-08 | 2022-08-05 | 南方医科大学 | Apelin-APJ抑制剂在制备治疗血睾屏障损伤药物中的应用 |
| EP4340865A4 (en) * | 2021-05-18 | 2025-04-02 | Attias, Eyal | USE OF ERYTHROPOIETIN (EPO) OR ERYTHROPOIESIS STIMULATING AGENT (ESA) FOR THE TREATMENT OF OSTEOMYELITIS, BONE INFECTION AND BONE INFLAMMATION |
| WO2023150878A1 (en) | 2022-02-09 | 2023-08-17 | Diamentis Inc. | Systems and methods for retinal stimulation and/or collecting retinal signal data |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4343782A (en) | 1978-04-20 | 1982-08-10 | Shapiro Howard M | Cytological assay procedure |
| US4658019A (en) | 1979-04-26 | 1987-04-14 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells |
| JPS6045849B2 (ja) * | 1980-08-25 | 1985-10-12 | 林原 健 | ヒトエリトロポエチンの製造方法 |
| NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
| US4835260A (en) * | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
| DE3729863A1 (de) | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
| WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
| DE3923963A1 (de) * | 1989-07-20 | 1991-01-31 | Behringwerke Ag | Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| AU646822B2 (en) | 1989-10-13 | 1994-03-10 | Kirin-Amgen Inc. | Erythropoietin isoforms |
| US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
| US5292654A (en) | 1990-12-13 | 1994-03-08 | Whitehead Institute For Biomedical Research | Mutant EPO receptor and uses therefor |
| JP3367666B2 (ja) * | 1990-12-17 | 2003-01-14 | カーディオヴァスキュラー イメイジング システムズ インコーポレイテッド | 低輪郭の遠位端部を有する血管カテーテル |
| US5416071A (en) | 1991-03-12 | 1995-05-16 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release containing epo and hyaluronic acid |
| US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| US5625035A (en) * | 1992-06-05 | 1997-04-29 | The Regents, University Of California | Erythropoietin binding protein from mammalian serum |
| US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
| US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
| DE4228839A1 (de) | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Verfahren zum Nachweis und zur Bestimmung von Mediatoren |
| US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| US6071970A (en) | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| KR960701650A (ko) * | 1993-04-29 | 1996-03-28 | 찰스 엠. 브룩 | 에리트로포이에틴 유사체 조성물 및 방법(Eythropoietin analog compositions and methods) |
| US5571787A (en) * | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
| US5700909A (en) * | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
| EP0776370B1 (en) | 1993-08-16 | 2006-04-19 | Jong Y. Lee | Human erythropoietin receptor fragment and antibodies thereto |
| IL110669A (en) | 1993-08-17 | 2008-11-26 | Kirin Amgen Inc | Erythropoietin analogs |
| US5859001A (en) | 1996-01-11 | 1999-01-12 | University Of Florida Research Foundation, Inc. | Neuroprotective effects of polycyclic phenolic compounds |
| US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
| US5830851A (en) * | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| US5604198A (en) | 1994-05-12 | 1997-02-18 | Poduslo; Joseph F. | Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents |
| US5763198A (en) | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
| US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
| US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
| AUPN780096A0 (en) | 1996-01-30 | 1996-02-22 | Medvet Science Pty. Ltd. | Cytokine antagonists and agonists |
| US5835382A (en) * | 1996-04-26 | 1998-11-10 | The Scripps Research Institute | Small molecule mimetics of erythropoietin |
| US20020052309A1 (en) | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
| AU736993B2 (en) | 1997-01-16 | 2001-08-09 | Novo Nordisk A/S | Practical in vitro sialylation of recombinant glycoproteins |
| EP0885613A1 (de) | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
| US6242570B1 (en) | 1997-07-10 | 2001-06-05 | Beth Israel Deaconess Medical Center | Production and use of recombinant protein multimers with increased biological activity |
| US6548296B1 (en) | 1997-07-23 | 2003-04-15 | Roche Diagnostics Gmbh | Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof |
| US6165783A (en) * | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
| WO1999028455A1 (de) * | 1997-12-03 | 1999-06-10 | Roche Diagnostics Gmbh | Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung |
| US6274158B1 (en) | 1998-02-04 | 2001-08-14 | Veronica L. Zaharia Czeizler | Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis |
| PT937456E (pt) | 1998-02-23 | 2004-10-29 | Cilag Ag Int | Dispersao lipossomal de eritropoietina |
| US6291661B1 (en) | 1998-07-02 | 2001-09-18 | Immunex Corporation | flt3-L mutants and method of use |
| US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| US6368453B1 (en) | 1999-03-18 | 2002-04-09 | Andritz Inc. | Chip feeding to a comminuted cellulosic fibrous material treatment vessel |
| US7309687B1 (en) | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
| TR200103785T2 (tr) * | 1999-04-13 | 2002-06-21 | The Kenneth S. Warren Institute, Inc. | Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi |
| US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| US20050170463A1 (en) | 1999-04-15 | 2005-08-04 | Abraham Bout | Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins |
| US20060099685A1 (en) | 1999-04-15 | 2006-05-11 | Yallop Christopher A | Recombinant expression of factor VIII in human cells |
| US20050164386A1 (en) | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
| US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| WO2000067776A1 (en) | 1999-05-11 | 2000-11-16 | Ortho-Mcneil Pharmaceuticals, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
| US20030118547A1 (en) * | 2000-01-27 | 2003-06-26 | Vandenberg Grant William | Composition for intestinal delivery |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| US20020061849A1 (en) | 2000-05-02 | 2002-05-23 | Soren Nielsen | Methods for treatment of diseases associated with inflammation under non-ischemic conditions |
| NZ522320A (en) | 2000-05-12 | 2007-03-30 | Neose Technologies Inc | In vitro modification of glycosylation patterns of recombinant glycopeptides |
| US7087224B2 (en) | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| KR100401296B1 (ko) | 2000-12-27 | 2003-10-11 | 드림바이오젠 주식회사 | 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법 |
| US6531121B2 (en) * | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| US7300916B2 (en) | 2001-02-27 | 2007-11-27 | Yoshiko Yasuda | Preventives/remedies for thickened scar, keloid or chronic arthritic diseases |
| JP2005503127A (ja) * | 2001-04-04 | 2005-02-03 | ジェンオディセ | エリスロポエチン遺伝子の新規ポリヌクレオチド及びポリペプチド |
| FR2823220B1 (fr) | 2001-04-04 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo) |
| US6930086B2 (en) | 2001-09-25 | 2005-08-16 | Hoffmann-La Roche Inc. | Diglycosylated erythropoietin |
| EA008220B1 (ru) | 2001-10-29 | 2007-04-27 | Круселл Холланд Б.В. | Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения |
| US6784154B2 (en) | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| KR100467750B1 (ko) | 2001-11-29 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
| KR100467751B1 (ko) | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
| ATE384785T1 (de) | 2001-12-07 | 2008-02-15 | Crucell Holland Bv | Herstellung von viren, virusisolaten, und impfstoffen |
| WO2003094858A2 (en) | 2002-05-13 | 2003-11-20 | Modigenetech Ltd. | Ctp-extended erythropoietin |
| US20060135854A9 (en) * | 2002-05-16 | 2006-06-22 | Sleepex Systems, Inc. | Sleep study software architecture |
| US7300915B2 (en) | 2002-06-05 | 2007-11-27 | The Regents Of The University Of California | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
| MXPA05000063A (es) | 2002-07-01 | 2005-04-08 | Kenneth S Warren Inst Inc | Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores. |
| US20050176627A1 (en) | 2002-09-09 | 2005-08-11 | Anthony Cerami | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| US20040091961A1 (en) | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
| JP2006521405A (ja) | 2003-03-27 | 2006-09-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 発作回復におけるエリトロポイエチンの使用 |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| US20060216757A1 (en) | 2003-04-25 | 2006-09-28 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
| JP2007505159A (ja) | 2003-05-19 | 2007-03-08 | ザ ケネス エス.ウォーレン インスティテュート,インコーポレーテッド | 延長された治療ウインドウを有する、応答性細胞、組織および器官の保護、回復および増強のための組織保護サイトカイン |
| CN1897959A (zh) | 2003-09-29 | 2007-01-17 | 沃伦药品公司 | 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子 |
| JP2008505184A (ja) | 2004-07-02 | 2008-02-21 | ザ ケネス エス.ウォーレン インスティテュート,インコーポレーテッド | 完全にカルバミル化されたエリトロポイエチンを生成する方法 |
| US20060135754A1 (en) | 2004-07-07 | 2006-06-22 | H. Lundbeck A/S | Novel carbamylated EPO and method for its production |
| CN101247822B (zh) | 2005-06-01 | 2012-10-17 | 新潟Tlo株式会社 | 含有epo衍生物的血液相关疾病的治疗剂 |
| EP1924276A4 (en) * | 2005-08-05 | 2009-07-22 | Araim Pharmaceuticals Inc | Antiperspirant peptides and their uses |
| KR100753979B1 (ko) * | 2005-09-07 | 2007-08-31 | 삼성전자주식회사 | Dna 검출 장치 |
| US7642078B2 (en) | 2005-12-28 | 2010-01-05 | Crucell Holland B.V. | Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby |
-
2002
- 2002-07-03 US US10/188,905 patent/US20030072737A1/en not_active Abandoned
-
2003
- 2003-07-03 ZA ZA200500131A patent/ZA200500131B/en unknown
- 2003-07-03 KR KR1020057000099A patent/KR20050049467A/ko not_active Ceased
- 2003-07-03 CA CA002491406A patent/CA2491406A1/en not_active Abandoned
- 2003-07-03 WO PCT/US2003/021350 patent/WO2004004656A2/en not_active Ceased
- 2003-07-03 AU AU2003247934A patent/AU2003247934A1/en not_active Abandoned
- 2003-07-03 CN CNA038204045A patent/CN1852731A/zh active Pending
- 2003-07-03 EP EP03763353A patent/EP1575528A4/en not_active Withdrawn
- 2003-07-03 EA EA200500149A patent/EA010371B1/ru not_active IP Right Cessation
- 2003-07-03 US US10/520,140 patent/US8404226B2/en not_active Expired - Fee Related
- 2003-07-03 PL PL377146A patent/PL377146A1/pl not_active Application Discontinuation
- 2003-07-03 JP JP2004520026A patent/JP2006515268A/ja not_active Withdrawn
- 2003-07-03 BR BRPI0311939-4A patent/BR0311939A/pt not_active IP Right Cessation
- 2003-07-03 MX MXPA05000060A patent/MXPA05000060A/es unknown
- 2003-07-04 AR ARP030102422A patent/AR040396A1/es unknown
-
2004
- 2004-12-29 IS IS7619A patent/IS7619A/is unknown
- 2004-12-30 IL IL16606704A patent/IL166067A0/xx unknown
-
2005
- 2005-02-01 NO NO20050550A patent/NO20050550L/no not_active Application Discontinuation
-
2011
- 2011-08-01 US US13/195,757 patent/US20120142589A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA010371B1 (ru) | 2008-08-29 |
| WO2004004656A2 (en) | 2004-01-15 |
| EP1575528A2 (en) | 2005-09-21 |
| CN1852731A (zh) | 2006-10-25 |
| MXPA05000060A (es) | 2005-04-08 |
| NO20050550L (no) | 2005-03-22 |
| KR20050049467A (ko) | 2005-05-25 |
| EP1575528A4 (en) | 2009-06-24 |
| AR040396A1 (es) | 2005-03-30 |
| US8404226B2 (en) | 2013-03-26 |
| JP2006515268A (ja) | 2006-05-25 |
| PL377146A1 (pl) | 2006-01-23 |
| AU2003247934A1 (en) | 2004-01-23 |
| CA2491406A1 (en) | 2004-01-15 |
| US20060034799A1 (en) | 2006-02-16 |
| IS7619A (is) | 2004-12-29 |
| WO2004004656A3 (en) | 2006-06-01 |
| IL166067A0 (en) | 2006-01-15 |
| ZA200500131B (en) | 2008-02-27 |
| US20120142589A1 (en) | 2012-06-07 |
| EA200500149A1 (ru) | 2006-08-25 |
| US20030072737A1 (en) | 2003-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004004656A3 (en) | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs | |
| BR9909583A (pt) | Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese | |
| BR0210056A (pt) | composições e métodos para tratamento de hiperplasia | |
| IL138979A0 (en) | Use of cannabinoids as anti-inflammatory agents | |
| AR023715A1 (es) | Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel | |
| BR0109150A (pt) | Método para administração de um anestésico local a um indivìduo em necessidade de um efeito anestésico local, emplastro, composição, e, recipiente | |
| MXPA01006917A (es) | Composicion topica que comprende n-acetilaldosaminas o acidos n-acetilaminos. | |
| BR0316203A (pt) | Uso de um agente antialérgico e um esteróide para tratar rinite alérgica | |
| FI953748A0 (fi) | Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina | |
| BRPI0411904B8 (pt) | formulações inaláveis para o tratamento de hipertensão pulmonar | |
| PT1239849E (pt) | Formulacoes farmaceuticas que compreendem resveratrol e a sua utilizacao | |
| EP1094781A4 (en) | COMPOSITIONS FOR THE RAPID AND NON-IRRITANT TRANSDERMAL ADMINISTRATION OF PHARMACEUTICALS AND METHOD FOR FORMULING THEREOF AND THEIR ADMINISTRATION | |
| BR9809951A (pt) | Método para tratamento da obesidade | |
| BR0210057A (pt) | Composição compreendendo agentes antifúngicos para tratar vulvovaginite e vaginose | |
| ES2149776T3 (es) | Modulacion, inducida por un morfogeno, de la respuesta inflamatoria. | |
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| AR008799A1 (es) | Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento | |
| BR9714484A (pt) | Composição cosmética para o cuidado da pele, processos cosméticos de redução ou prevenção de condições de pele oleosa, de redução ou prevenção de secreção sebácea proveniente de sebócitos, de proteção da pele contra a atividade dos radicais livres, de obtenção de uma fração alcoólica de gugulipìdeo, e, uso de um agente anti-sebáceo/ antioxidante | |
| DE60040753D1 (de) | Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden | |
| BRPI0406796A (pt) | Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina | |
| SE0300971D0 (sv) | Nitric oxide in treatment of inflammation | |
| BRPI0413410A (pt) | co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer | |
| CO5570661A2 (es) | Combinaciones que comprenden inhibidores de cox-2 y aspirina | |
| BR0201524A (pt) | Tratamento de combinação para ansiedade e depressão | |
| BR0310061A (pt) | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011. |